AR066913A1 - Metodos y composiciones para inducir la apoptosis en celulas cancerosas - Google Patents
Metodos y composiciones para inducir la apoptosis en celulas cancerosasInfo
- Publication number
- AR066913A1 AR066913A1 ARP080102431A ARP080102431A AR066913A1 AR 066913 A1 AR066913 A1 AR 066913A1 AR P080102431 A ARP080102431 A AR P080102431A AR P080102431 A ARP080102431 A AR P080102431A AR 066913 A1 AR066913 A1 AR 066913A1
- Authority
- AR
- Argentina
- Prior art keywords
- heavy chain
- light chain
- methods
- amino acid
- variable region
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 abstract 2
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 241000282412 Homo Species 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Dichos anticuerpos anti-DR5 poseen inmunogenicidad minimizada en humanos. Métodos para usar dichos anticuerpos. Reivindicacion 1: Un anticuerpo que se une al Receptor do Muerte 5 (DR5), donde el anticuerpo comprende a) una region variable de la cadena pesada que comprende un segmento V humano de cadena pesada, una region determinante de la complementariedad 3 de cadena pesada (CDR3), y una region de marco de cadena pesada 4 (FR4) y (b) una region variable de la cadena liviana que comprende un segmento V humano de cadena liviana, una CD3 de cadena liviana y una FR4 de cadena liviana, donde i) La CD3 de CDR3 de cadena pesada comprendo la secuencia de aminoácidos HEEGI (SEC ID N°: 49) y ii) la region variable CD3 de la cadena liviana comprende la secuencia de aminoácidos QXHXXTP (SEC ID N°: 50), en la cual x indica cualquier aminoácido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94286207P | 2007-06-08 | 2007-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066913A1 true AR066913A1 (es) | 2009-09-23 |
Family
ID=39730803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102431A AR066913A1 (es) | 2007-06-08 | 2008-06-06 | Metodos y composiciones para inducir la apoptosis en celulas cancerosas |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR066913A1 (es) |
| PE (1) | PE20090765A1 (es) |
| TW (1) | TW200911835A (es) |
| WO (1) | WO2008154439A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ701444A (en) | 2010-08-27 | 2016-06-24 | Gilead Biologics Inc | Antibodies to matrix metalloproteinase 9 |
| MD20140107A2 (ro) * | 2012-02-29 | 2015-03-31 | Gilead Biologics, Inc. | Anticorpi împotriva metaloproteinazei 9 din matrice |
| WO2013130905A1 (en) * | 2012-02-29 | 2013-09-06 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
| CN106397594B (zh) * | 2016-10-25 | 2019-06-04 | 中国药科大学 | 一种全人源的抗人死亡受体5的激动剂单链抗体及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5869619A (en) * | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| TWI318983B (en) * | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| JP2005538706A (ja) * | 2001-07-12 | 2005-12-22 | ジェファーソン フーテ， | スーパーヒト化抗体 |
| JP2006514096A (ja) * | 2002-11-27 | 2006-04-27 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 癌細胞においてアポトーシスを誘導するための方法および組成物 |
| AU2005207003C1 (en) * | 2004-01-20 | 2013-06-13 | Humanigen, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| KR20070010046A (ko) * | 2004-04-06 | 2007-01-19 | 제넨테크, 인크. | Ｄｒ5 항체 및 그의 용도 |
-
2008
- 2008-06-06 WO PCT/US2008/066202 patent/WO2008154439A1/en not_active Ceased
- 2008-06-06 TW TW097121278A patent/TW200911835A/zh unknown
- 2008-06-06 PE PE2008000970A patent/PE20090765A1/es not_active Application Discontinuation
- 2008-06-06 AR ARP080102431A patent/AR066913A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008154439A1 (en) | 2008-12-18 |
| TW200911835A (en) | 2009-03-16 |
| PE20090765A1 (es) | 2009-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| ES2657226T3 (es) | Anticuerpo monoclonal anti-VEGF y composición farmacéutica que comprende dicho anticuerpo | |
| AR079336A1 (es) | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) | |
| AR052889A1 (es) | Anticuerpos contra interleuquina-1 beta | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| PE20080035A1 (es) | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina | |
| PE20141435A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| AR083747A1 (es) | Anticuerpos anti-il-23 | |
| CL2008003782A1 (es) | Anticuerpo bivalente bioespecifico que comprende la cadena ligera y pesada de un anticuerpo que se une a un primer antigeno donde el dominio ch3 se reemplaza por ch1, y la cadena ligera y pesada de un anticuerpo que se une a un segundo antigeno, en el que el dominio ch3 esta reemplazado por cl; metodo de preparacion; y composicion. | |
| AR075604A1 (es) | Anticuerpos contra un ligando que induce proliferacion (april) | |
| PE20121552A1 (es) | Anticuerpos monoclonales anti cea humanizados de afinidad madura | |
| UY30260A1 (es) | Anticuerpos dirigidos contra upar y usos de los mismos | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| AR109355A2 (es) | Moléculas de unión al receptor ox40 humano | |
| ES2572177T3 (es) | Anticuerpos neutralizantes anti-B7RP1 humanos | |
| PE20061323A1 (es) | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos | |
| PE20140196A1 (es) | Anticuerpos anti-cd37 | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| PE20180042A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| PE20081478A1 (es) | Anticuerpos cd44 | |
| AR096895A2 (es) | Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp) | |
| MY166776A (en) | Humanised anti-ctla4 antibodies | |
| PE20140247A1 (es) | Anticuerpos anti-cd38 | |
| PE20141787A1 (es) | Composiciones anti-cgrp y uso de las mismas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |